Pfizer’s Bavencio (avelumab) + Axitinib Dual Regimen Receive EC’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

 Pfizer’s Bavencio (avelumab) + Axitinib Dual Regimen Receive EC’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Pfizer’s Bavencio (avelumab) + Axitinib Dual Regimen Receive EC’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Shots:

  • The approval is based in P-III JAVELIN Renal 101 study assessing Bavencio + Axitinib vs Sunitinib in 886 patients with untreated advanced or metastatic RCC with all IMDC prognostic risk groups and irrespective of PD-L1 expression
  • The P-III JAVELIN Renal 101 study resulted in improvement in PFS (13.3 vs 8.0 mos.) with a median follow-up for OS is 19mos. The EC’s approval follows the FDA’s approval of Bavencio + Axitinib for 1L treatment of advanced RCC in May’2019
  • Bavencio is an anti-PD-L1 antibody, act by blocking the interaction of PD-L1 with PD-1 receptors, demonstrating T cell-mediated antitumor immune response suppression in preclinical models. In Nov’2014, Merck KGaA & Pfizer collaborated to co-develop & co-commercialize Bavencio

Click here to­ read full press release/ article | Ref: Pfizer | Image: The Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post